Pattern of Recurrence and Patient Survival after Perioperative Chemotherapy with 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) for Locally Advanced Esophagogastric Adenocarcinoma in Patients Treated Outside Clinical Trials.
Torben GlatzRasmus VerstJasmina KuvendjiskaPeter BronsertHeiko BeckerJens HöppnerBirte KulemannPublished in: Journal of clinical medicine (2020)
Real-life application of FLOT shows oncologic results comparable to clinical trials. Recurrence after FLOT and surgery for EGAC occurs predominantly early within the first two years after surgery and in the form of distant organ metastasis for esophageal tumors or peritoneal carcinomatosis for gastric tumors.
Keyphrases
- clinical trial
- locally advanced
- rectal cancer
- minimally invasive
- phase ii
- squamous cell carcinoma
- coronary artery bypass
- lymph node
- patients undergoing
- case report
- cardiac surgery
- open label
- double blind
- radiation therapy
- phase iii
- radical prostatectomy
- robot assisted
- study protocol
- coronary artery disease
- randomized controlled trial
- chemotherapy induced